Last reviewed 2026-04-23 · How we verify

BGB-290

PARP inhibitor

PARP inhibitor Used for Urothelial carcinoma.

At a glance

Mechanism of action

BGB-290 is a potent inhibitor of PARP1 and PARP2, enzymes involved in DNA repair and genomic stability.

Approved indications

• Urothelial carcinoma

Common side effects

• Fatigue
• Nausea
• Diarrhea

Key clinical trials

• Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies (PHASE3)
• Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer (PHASE3)
• BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas (PHASE1)
• Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer (PHASE1)
• Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors (PHASE1)
• A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma (PHASE1, PHASE2)
• Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors (PHASE1, PHASE2)
• BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• BGB-290 CI brief — competitive landscape report
• BGB-290 updates RSS · CI watch RSS
• BeiGene portfolio CI